Photo via City AM

Celebrity-backed cancer treatment venture eyes London listing

Read the original at City AM ↗
Cite

Grice, M. (2026, November 16). Celebrity-backed cancer treatment venture eyes London listing. City AM. https://www.cityam.com/celebrity-backed-cancer-treatment-venture-eyes-london-listing/

Dated from the outlet's own feed. Check the original for its byline.

City AM · collected 2026-11-16 · by Maisie Grice

Quick Summary

Ellipses Pharma, a clinical-stage oncology company founded by British biotech entrepreneur Sir Chris Evans, plans to list on the London Stock Exchange via a reverse takeover of Wolfram Resources, targeting a valuation between £450m and £500m. Major investors include Abu Dhabi’s sovereign wealth fund with a 45% stake and celebrities like Jimmy Carr and Andrew Lloyd Webber. The company, which has invested about £185m in its drug pipeline, is set to appoint non-executives to its board before the listing, with a formal announcement expected soon.
Written by AI on 2026-11-16, from this article's own text only (the story summary below draws on all the coverage).

AI analysis

Story summary

Ellipses Pharma, a clinical-stage oncology company founded by British biotech entrepreneur Sir Chris Evans and backed by Middle Eastern wealth and celebrity investors, is planning to list on the London Stock Exchange with a valuation of between £450m and £500m. The company's investors include Sir Chris Evans, housebuilder Steve Morgan, and Scottish entrepreneur Sir Tom Hunter's investment vehicle West Coast Capital, along with celebrities Jimmy Carr and Andrew Lloyd Webber. Abu Dhabi’s sovereign wealth fund, Mubadala Investment Company, holds a 45% stake in Ellipses. The company launched its clinical trial programme in the UAE in December 2024 and is expected to make a formal announcement about the listing soon.

Written for “Celebrity Backed Cancer Treatment Venture” on 2026-11-21, grounded in this article and the 0 other(s) covering the same event.

Compared with similar articles

Nothing to compare against. No article is close enough to this one for the pipeline to have linked or judged the pair.

Story

Celebrity Backed Cancer Treatment Venture
Health · 1 article(s) covering the same event.
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
16
sentences that state something as happening or true
Uncertain
12%
2 of 16 hedged ("reportedly", "may", "according to")
Leaning
not political
takes no side on a contested political question
Publisher signals
95/100
City AM's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
1
Health
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-11-16 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

City AM · 404 article(s) · 0 correction(s) detected
No corrections detected for this publisher. That may mean careful reporting, or simply that nothing has been checked.

Who wrote this

Maisie Grice
15 article(s) here · 1 carrying a prediction
Dashing hopes Anthropic’s listing was initially billed as a defining moment for the AI boom and wider global markets, giving investors the chance to gain exposure to a company at technology’s frontier. But analysts said its debut would likely not be enough to dissipate growing fears on the sustainability of the debt-fuelled boom. Neil WIlson, UK investor strategist at Saxo, said: “It was a pretty brutal selloff across tech…
2026-11-20 · assertive framing · Anthropic shares plunge as AI fears erase debut gains
The blockbuster debut couldn’t sweep those worries under the rug.” Anthropic shares popped
2026-11-20 · assertive framing · Tech stocks fall as Anthropic fails to revive AI trade
Simon Belsham, chief client officer at Hargreaves Lansdown, said: “The debate for future listings isn’t whether a global retail offer can be done, but why a company wouldn’t offer individual investors access at IPO and attract a broader and more diverse shareholder base for the listing company.”
But prices began to ease somewhat after the initial opening surge, bouncing between $100 and $98 per share, meaning the company’s valuation may end at a different level as the share price continues to rise and fall.
Anthropic is set to make its hotly anticipated Nasdaq debut in less than 24 hours, with the frontier model lab seeking to raise as much as $90.4bn at a $1.4 trillion (£1.1 trillion) valuation, marking it as one of the largest listings in history.
Analysts have warned that Nvidia’s interim chief executive Colette Kress must deliver tight forward guidance and a clear plan in the firm’s results in order to reverse losses and restore stability, arguing a rise in earnings alone will not be enough.
The chipmaker is set to release its latest quarterly results on 17 November.
A formal announcement could be made as soon as this week.
Roughly 1,000 jobs are set to be cut by mid-2027, representing around 10 per cent of the workforce.
The financial watchdog’s proposals to relax pension charge cap rules could help boost investment in start-ups and private companies, bosses have said, after efforts to unleash a wave of investment from Britain’s retirement funds have stalled in recent years.
Also by Maisie Grice
Nothing else under this byline is closely related to this article, so these are simply their most recent.
All 15 articles by Maisie Grice →

Topics

Ellipses Ellipses Pharma London Middle Eastern the London Stock Exchange

Subjects

Ellipses ORG · 5× London GPE · 5× Evans PERSON · 2× British NORP · 1× Chris Evans PERSON · 1× Ellipses Pharma ORG · 1× Middle Eastern NORP · 1× Redrow ORG · 1× The Times ORG · 1× the London Stock Exchange ORG · 1×

Narrative

It launched a clinical trial programme in the UAE in December 2024. Seeing off the US Evans, who has overseen the founding and listing of numerous biotech companies including Enzymatix and Celsis, had been weighing up a listing away from London.
framing: assertive · carried by 1 article(s) · first seen 2026-11-16
A formal announcement could be made as soon as this week.
2026-11-16 · City AM
Celebrity-backed cancer treatment venture eyes London listing · assertive framing

Claims (16 extracted, 2 hedged)

A cancer drug venture backed by a group of celebrity investors and Middle Eastern wealth is planning to list on the London Stock Exchange. asserted
venture → back → Exchange
Ellipses Pharma, a clinical-stage oncology venture founded by renowned British biotech entrepreneur Sir Chris Evans and, is preparing to reverse into a brand-new company, targeting a listing valuation of between £450m and £500m, according to reports in The Times. uncertain
Pharma → found → Times
The company’s investors include Evans, founder of housebuilder Redrow, Steve Morgan, and Scottish entrepreneur Sir Tom Hunter’s investment vehicle West Coast Capital. asserted
investors → include → Redrow
Celebrity investors have also thrown their weight behind Ellipses, including comedian Jimmy Carr and Andrew Lloyd Webber. But the venture’s single largest investor is Abu Dhabi’s sovereign wealth fund, which holds a 45 per cent stake. asserted
which → throw → stake
Waleed al- Mokarrab al-Muhairi, deputy chief executive of Mubadala Investment Company, the nation’s sovereign wealth fund, sat on the firm’s board until March 2025. asserted
Muhairi → sit → March
It launched a clinical trial programme in the UAE in December 2024. Seeing off the US Evans, who has overseen the founding and listing of numerous biotech companies including Enzymatix and Celsis, had been weighing up a listing away from London. asserted
who → launch → London
The entrepreneur was considering the Nasdaq for Ellipses’ home, while Hong Kong was also floated as a possible venue in 2025. asserted
Kong → consider → 2025
But Ellipses is now targeting a listing in London as soon as February through a reverse takeover of Wolfram Resources, a cash shell which had been focused on investment in precious metals exploration across central Asia. asserted
which → target → Asia
Private bank Berenberg is reported to have been appointed to help manage the deal, while Ellipses is also preparing to appoint non-executives to its board before a listing. asserted
Ellipses → report → listing
Royal Bank of Canada and Pharma Ventures, an M&A advisory firm, are understood to have been lined up to advise on potential out-license deals with big pharma companies. asserted
Bank → understand → companies
A formal announcement could be made as soon as this week. uncertain
announcement → make → week
Boost for London Reverse takeovers offer a fast-track route to raising money on public markets compared to an initial public offering and the Nasdaq has been hit with a flurry of such deals over the course of this year. asserted
Nasdaq → offer → year
A successful listing would also provide London with a much needed boost, as it continues to feel the shocks of a wave of delistings coupled with a continued exodus of IPOs. asserted
it → provide → IPOs
In particular, it would lift London’s biotech and pharmaceutical sector, which has seen companies eye opportunities in America. asserted
companies → lift → America
FTSE heavyweight Astrazeneca has pivoted closer to the US over the last year, upgrading its listing on the New York stock Exchange. asserted
Astrazeneca → pivot → Exchange
Ellipses employs around 40 people, mainly from big pharma companies, and has invested roughly £185m in its drug pipeline. asserted
Ellipses → employ → pipeline
Give feedback · no sign-in needed

No sign-in needed for now. Your note is sent without a name, so it cannot be answered.

History Support